Zobrazeno 1 - 10 of 48 pro vyhledávání: '"Drexler DM"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Technical brief. Improvements to the sample manipulation design of a LEAP CTC HTS PAL autosampler used for high-throughput qualitative and quantitative liquid chromatograpy-mass spectrometry assays.
Autor: Drexler DM, Edinger KJ, Mongillo JJ
Publikováno v: JALA: Journal of the Association for Laboratory Automation; Jun2007, Vol. 12 Issue 3, p152-156, 5p
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects.
Autor: Shen H; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.) hong.shen1@bms.com., Holenarsipur VK; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Mariappan TT; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Drexler DM; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Cantone JL; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Rajanna P; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Singh Gautam S; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Zhang Y; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Gan J; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Shipkova PA; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Marathe P; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.)., Humphreys WG; Metabolism and Pharmacokinetics Department (H.S., Y.Z., J.G., P.M., W.G.H.) and Bioanalytical and Discovery Analytical Sciences Department (P.A.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bangalore, India (V.K.H., T.T.M., P.R., S.S.G.); and Bioanalytical and Discovery Analytical Sciences Department, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., J.L.C.).
Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2019 Jan; Vol. 368 (1), pp. 136-145. Date of Electronic Publication: 2018 Oct 25.
Zobrazit plný text záznamu
7
Akademický článek
Synergistic inhibition of Aβ production by combinations of γ-secretase modulators.
Autor: Robertson AS; Neuroscience Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Iben LG; Neuroscience Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Wei C; Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Meredith JE Jr; Neuroscience Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Drexler DM; Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Banks M; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Vite GD; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Olson RE; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Thompson LA; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Albright CF; Neuroscience Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Ahlijanian MK; Neuroscience Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA., Toyn JH; Neuroscience Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06437, USA. Electronic address: jeremy.toyn@yale.edu.
Publikováno v: European journal of pharmacology [Eur J Pharmacol] 2017 Oct 05; Vol. 812, pp. 104-112. Date of Electronic Publication: 2017 Jul 08.
Zobrazit plný text záznamu
8
Akademický článek
Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
Autor: Shen H; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India hong.shen1@bms.com., Chen W; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Drexler DM; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Mandlekar S; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Holenarsipur VK; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Shields EE; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Langish R; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Sidik K; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Gan J; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Humphreys WG; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Marathe P; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India., Lai Y; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India.
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2017 Aug; Vol. 45 (8), pp. 908-919. Date of Electronic Publication: 2017 Jun 02.
Zobrazit plný text záznamu
9
Akademický článek
Tiered analytics for purity assessment of macrocyclic peptides in drug discovery: Analytical consideration and method development.
Autor: Qian Cutrone JJ; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. Electronic address: jingfang.cutrone@bms.com., Huang XS; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Kozlowski ES; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Bao Y; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Wang Y; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Poronsky CS; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Drexler DM; Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Tymiak AA; Bristol-Myers Squibb Co., Research and Development, P.O. Box 4000, Princeton, NJ 08543, USA.
Publikováno v: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2017 May 10; Vol. 138, pp. 166-174. Date of Electronic Publication: 2017 Feb 03.
Zobrazit plný text záznamu
10
Akademický článek
Phosphocholine conjugation: an unexpected in vivo conjugation pathway associated with hepatitis c ns5b inhibitors featuring a bicyclo[1.1.1]pentane.
Autor: Zhuo X; Bristol-Myers Squibb; xiaoliang.zhuo@bms.com., Cantone JL; Bristol-Myers Squibb;, Wang Y; Bristol-Myers Squibb;, Leet JE; Bristol-Myers Squibb;, Drexler DM; Bristol-Myers Squibb;, Yeung KS; Bristol-Myers Squibb;, Huang XS; Bristol-Myers Squibb;, Eastman KJ; Bristol-Myers Squibb;, Parcella KE; Bristol-Myers Squibb;, Mosure KW; Bristol-Myers Squibb;, Soars MG; Bristol-Myers Squibb;, Kadow JF; Bristol-Myers Squibb;, Johnson BM; Bristol-Myers Squibb Company.
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2016 Aug; Vol. 44 (8), pp. 1332-1340. Date of Electronic Publication: 2016 Mar 09.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje